Continuing to improve outcomes of men with metastatic prostate cancer

Nature Reviews Clinical Oncology, Published online: 16 July 2019; doi:10.1038/s41571-019-0254-9In the TITAN and ENZAMET trials, unprecedented overall survival outcomes were observed in patients with metastatic castration-sensitive prostate cancer receiving an agent targeting the androgen receptor in addition to androgen-deprivation therapy early in the course of their disease. Herein, I discuss both trials in the context of other studies in this disease setting.

Source: Nature Reviews Clinical Oncology - July 15, 2019 Category: Cancer & Oncology Authors: Fred Saad Source Type: research